[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Darling et al., 2011 - Google Patents

Quantitation of pretreatment serum interferon‐γ–inducible protein‐10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response

Darling et al., 2011

View PDF
Document ID
4140145970706183171
Author
Darling J
Aerssens J
Fanning G
McHutchison J
Goldstein D
Thompson A
Shianna K
Afdhal N
Hudson M
Howell C
Talloen W
Bollekens J
De Wit M
Scholliers A
Fried M
Publication year
Publication venue
Hepatology

External Links

Snippet

Polymorphisms of the IL28B gene are highly associated with sustained virological response (SVR) in patients with chronic hepatitis C treated with peginterferon and ribavirin. Quantitation of interferon‐γ–inducible protein‐10 (IP‐10) may also differentiate antiviral …
Continue reading at aasldpubs.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/576Immunoassay; Biospecific binding assay for hepatitis
    • G01N33/5767Immunoassay; Biospecific binding assay for hepatitis non-A, non-B hepatitis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
    • C12Q1/701Specific hybridization probes
    • C12Q1/706Specific hybridization probes for hepatitis
    • C12Q1/707Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]

Similar Documents

Publication Publication Date Title
Darling et al. Quantitation of pretreatment serum interferon‐γ–inducible protein‐10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response
Zeuzem et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa
Chemello et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C
Bitetto et al. Complementary role of vitamin D deficiency and the interleukin‐28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C
Sarrazin et al. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy
Cheng et al. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection
Dahari et al. Hepatitis C viral kinetics in the era of direct acting antiviral agents and interleukin-28B
Shaker et al. Polymorphisms in interleukin‐10 and interleukin‐28 B genes in E gyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin‐therapy
JP2010520744A (en) Method and kit for examining drug sensitivity of patients infected with HCV
Onto et al. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon‐α therapy in Japanese patients with chronic hepatitis C
Kosaka et al. Emergence of resistant variants detected by ultra‐deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1
Zhang et al. IFNL 3 (IL 28B) polymorphism does not predict long‐term response to interferon therapy in HB eAg‐positive chronic hepatitis B patients
Mizokami et al. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon‐α 2α therapy in Japanese patients with chronic hepatitis C
YEN et al. Mutations in the interferon sensitivity‐determining region (nonstructural 5A amino acid 2209–2248) in patients with hepatitis C‐1b infection and correlating response to combined therapy of pegylated interferon and ribavirin
Lee Indicators and predictors of response to anti‐viral therapy in chronic hepatitis C
JP2016136965A (en) Predictive value of il28b gene polymorphism combined with pre-treatment serum ip-10 quantification for response to peginterferon and ribavirin enhanced in comparison with any of these biomarkers alone
Hai et al. Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated‐interferon and ribavirin
Matsuura et al. Serum interferon‐gamma‐inducible protein‐10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C
Fukutomi et al. Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy
Kozuka et al. Changes in sequences of core region, interferon sensitivity‐determining region and interferon and ribavirin resistance‐determining region of hepatitis C virus genotype 1 during interferon‐alpha and ribavirin therapy, and efficacy of retreatment
Ogawa et al. Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection
Darling et al. Quantitation of pretreatment serum IP-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response
Hassanien et al. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients
Fathy et al. Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients
Abe et al. Factors associated with sustained virological response in 24‐week telaprevir‐based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype